CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Supriya Lifescience Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Supriya Lifescience Ltd
Sonawala Road Goregoan
207/208, Udyog Bhavan
Phone: +91 2240332727p:+91 2240332727 MUMBAI, 400 063  India Ticker: SUPRIYASUPRIYA
Business Summary
Supriya Lifescience Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs). The Company is primarily engaged in manufacturing of bulk drugs and pharmaceutical chemicals. The Company exports its products in the antihistamine, anesthetics and anti-asthma therapy categories to approximately 86 countries. The Company's product portfolio consists of approximately 38 niche API products that address remedies in therapeutic segments, such as antihistamine, analgesic, vitamin, anesthetics and anti-asthmatics, among others. The Company has manufacturing facilities located in Maharashtra. Its products include Chlorphenamine Maleate, Pheniramine Maleate, Brompheniramine Maleate, Dexchlorpheniramine Maleate, Mepyramine / Pyrilamine Maleate, Dexbrompheniramine Maleate, Cetirizine DiHCL, Diphenhydramine HCL, Bisoprolol Fumarate, Nicorandil, Mecobalamin, Hydroxocobalamin Sulphate, Hydroxocobalamin Acetate, and Hydroxocobalamin Hydrochloride, among others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20233/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries
5912 Drug stores and proprietary stores

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Managing Director Satish W.Wagh 66 6/1/2019 6/1/2019
Chief Executive Officer Rajeev K.Jain 10/3/2022 10/3/2022
Chief Financial Officer KrishnaRaghunathan 1/23/2023 1/23/2023
11 additional Officers and Directors records available in full report.

Business Names
Business Name
543434
SUPRIYA

General Information
Number of Employees: 392 (As of 3/31/2023)
Outstanding Shares: 80,482,800 (As of 9/30/2023)
Shareholders: 97,247
Stock Exchange: NSE
Fax Number: +91 2226860011


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 28, 2024